Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 10/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 10/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 10/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 8/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 8/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 7/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bretazenil SCHEMBL29716315 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7271384 | 0.95 | GABRG2 (0.91) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7264139 | 0.90 | GABRG2 (0.81) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7263536 | 0.89 | GABRG2 (0.80) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7263573 | 0.89 | GABRG2 (0.80) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7265302 | 0.89 | GABRG2 (0.80) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7264142 | 0.88 | GABRG2 (0.79) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7272495 | 0.88 | GABRG2 (0.79) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7263614 | 0.88 | GABRG2 (0.79) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL7263551 | 0.88 | GABRG2 (0.79) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 885 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240390311-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-28 | — | — | US | claimed |
| EP-4405049-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | The Regents of the University of California (US) | 2024-07-31 | — | — | EP | claimed |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| US-20230381125-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-30 | — | — | US | claimed |
| EP-4247386-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| EP-4217002-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | The Regents of the University of California (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2023101899-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING SJOGREN'S SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023048781-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-30 | — | — | WO | claimed |
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-29 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0789567-A4 | A METHOD FOR TREATING VASCULAR HEADACHES | GEN HOSPITAL CORP (US) | 1999-01-13 | — | — | EP | claimed |
| US-5767117-A | BINDING OF AN AGONIST TO A 4-AMINOBUTYRIC ACID RECEPTOR AT THE BENZODIAZEPINE SITE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-06-16 | — | — | US | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0789567-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1997-08-20 | — | — | EP | claimed |
| WO-1996015782-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0488044-B1 | An imidazobenzodiazepin for treating sleep disorders | HOFFMANN LA ROCHE (CH) | 1996-02-14 | — | — | EP | claimed |
| US-5221672-A | Therapy for sleep disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-06-22 | — | — | US | claimed |
| EP-0488044-A1 | An imidazobenzodiazepin for treating sleep disorders | F. HOFFMANN-LA ROCHE AG (CH) | 1992-06-03 | — | — | EP | claimed |
| EP-0059391-A1 | Imidazodiazepines, process for their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-09-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | GABRB2, GABRA4, GABRB1 | GABRG2 16/4885GABRB3 4/4885GABRA5 8/4885 |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | GABRG2 14/4885GABRB3 9/4885GABRA5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.